Cargando…

Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings

BACKGROUND: Much of the prior research on viral failure (VF) with integrase inhibitor (INSTI) therapy is based on results from trials rather than clinical care settings and little is known about recently approved medications such as dolutegravir (DTG). We compared VF in persons living with HIV (PLWH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nance, Robin, Vannappagari, Vani, Smith, Kimberly, Johannes, Catherine, Calingaert, Brian, Saltus, Catherine, Boswell, Stephen, Rodriguez, Benigno, Moore, Richard, Eron, Joseph, Geng, Elvin, Mathews, W Christopher, Saag, Michael S, Kitahata, Mari, Delaney, JaC, Crane, Heidi M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632278/ http://dx.doi.org/10.1093/ofid/ofx162.095

Ejemplares similares

Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir
por: Vannappagari, Vani, et al.
Publicado: (2019)

2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
por: Pierone, Gerald, et al.
Publicado: (2019)

1555 Factors Associated with the Selection of Initial Antiretroviral Therapy: Real-world Channeling
por: Saag, Michael, et al.
Publicado: (2014)

1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
por: Yan, Lei, et al.
Publicado: (2022)

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
por: Crawford, Melissa, et al.
Publicado: (2020)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study
por: Harding, Barbara N, et al.
Publicado: (2020)

Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus–Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study
por: Kim, H Nina, et al.
Publicado: (2019)

Psychiatric Symptoms in Patients Receiving Dolutegravir
por: Fettiplace, Anna, et al.
Publicado: (2017)

Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice
por: Drozd, Daniel R., et al.
Publicado: (2017)

Racial and ethnic disparities in COVID-19 disease incidence independent of comorbidities, among people with HIV in the US
por: Bender Ignacio, RA, et al.
Publicado: (2021)

Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load
por: Poon, Art F. Y., et al.
Publicado: (2011)

Genetic architecture of cardiometabolic risks in people living with HIV
por: Chang, Haoxiang, et al.
Publicado: (2020)

Correction to: Genetic architecture of cardiometabolic risks in people living with HIV
por: Cheng, Haoxiang, et al.
Publicado: (2021)

74. Maternal Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: The Antiretroviral Pregnancy Registry (APR)
por: Vannappagari, Vani, et al.
Publicado: (2021)

Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS)
por: Feinstein, Matthew J., et al.
Publicado: (2019)

Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study
por: Harding, B. N., et al.
Publicado: (2020)

The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database
por: Johannes, Catherine B., et al.
Publicado: (2022)

Fructosamine and Hemoglobin A1c Correlations in HIV-Infected Adults in Routine Clinical Care: Impact of Anemia and Albumin Levels
por: Duran, Luisa, et al.
Publicado: (2015)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
por: Ward, Douglas, et al.
Publicado: (2020)

Epidemiology of Adult Soft-Tissue Sarcomas in Germany
por: Saltus, Catherine W., et al.
Publicado: (2018)

Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States
por: Saltus, Catherine W., et al.
Publicado: (2019)

Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”
por: Saltus, Catherine W., et al.
Publicado: (2019)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens
por: Rodrigues, Janine, et al.
Publicado: (2023)

1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
por: Pierone, Gerald, et al.
Publicado: (2022)

Substance use and HIV stage at entry into care among people with HIV
por: Parrish, Canada, et al.
Publicado: (2021)

Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA(®) Observational Database
por: Pierone, Gerald, et al.
Publicado: (2019)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen
por: Badat, Ahmed, et al.
Publicado: (2022)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
por: Raffi, François, et al.
Publicado: (2015)

Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020
por: Shapiro, Adrienne E., et al.
Publicado: (2021)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?
por: Capetti, Amedeo F, et al.
Publicado: (2019)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rrem2gaebedbd3p5betcukmbng